Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Introduction: Approximately 20% of patients (pts) with classic Hodgkin lymphoma (cHL) relapse after frontline therapy. Salvage chemotherapy and autologous stem cell transplant (ASCT) have cure rates of 60%–70%. Prior to brentuximab vedotin (BV) and checkpoint inhibitors (CPI), the median overall survival (OS) of pts with cHL relapse after ASCT was 2–3 years.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
